BD Launches BD MAXâ„¢ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians
MILAN, May 6, 2011 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), today announced the European launch of the BD MAX™ Open System for molecular testing, which will enable laboratories to run both laboratory and BD- developed assays and offer enhanced testing services that elevate the standards of care at their institutions.
BD made the launch announcement on the opening day of the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy (ECCMID/ICC) in Milan, Italy.
"In a world with ever-evolving pathogens, laboratories need to provide clinicians with fast, accurate and actionable diagnostic information that will save patient lives," said Tom Polen, President of BD Diagnostics - Diagnostic Systems. "The new completely open, state-of-the-art BD MAX System empowers laboratories to automate their unique internally developed molecular assays, while accessing a rich and growing menu of world-class assays from BD and our leading assay development partners."
BD MAX is the first and only fully automated, open, bench-top molecular testing workstation able to perform both IVD/CE and laboratory-developed tests. The BD MAX System gives clinical laboratory professionals new ability to help their institutions respond to emerging threats, such as new strains of deadly drug-resistant bacteria or respiratory illnesses.
"BD's strategy is to make BD MAX the laboratory equivalent of a smartphone," said Polen. "We are working with leading assay development companies from around the world to develop a constantly growing, content-rich menu of tests that deliver critical information to caregivers faster and more accurately than current methods. Our plan is to make the BD MAX System an indispensible tool that no laboratory professional will want